HOME ·

01093.HK

CSPC PHARMA (01093.HK): Recombinant respiratory syncytial virus vaccine SYS6057 approved for clinical trials in the US
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-25
CSPC PHARMA(01093.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 6.09 billion, YoY increase of 139.19%
Tags：
CSPC PHARMA01093.HKprofit growth
2026-08-20
CSPC PHARMA (01093.HK): NDA for KN026 Plus HB1801 as First-Line Treatment for Advanced Breast Cancer Accepted by NMPA
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-18
CSPC Pharmaceutical Group (01093.HK): Receives US$30 Million Upfront Payment Under siRNA Collaboration Agreement with AstraZeneca
Tags：
CSPC Pharmaceutical Group01093.HK
2026-08-12
CSPC Pharmaceutical Group (01093.HK): Phase I Clinical Trial of SYS6063 for Relapsed and Refractory Systemic Lupus Erythematosus Initiated at First Study Site in China
Tags：
CSPC Pharmaceutical Group01093.HK
2026-08-11
CSPC Pharmaceutical Group (01093.HK): Monkeypox mRNA Vaccine SYS6037 Granted US FDA Clinical Trial Approval
Tags：
CSPC Pharmaceutical Group01093.HK
2026-08-10
CSPC PHARMA(01093.HK): Receives USD10‑Million Milestone Payment from AstraZeneca
Tags：
CSPC PHARMA01093.HKAstraZenecastrategic cooperation
2026-08-05
CSPC PHARMA(01093.HK): Joint Venture Established with AstraZeneca, Holding 51% Stake to Co‑Build Biologics Manufacturing Base
Tags：
CSPC PHARMA01093.HKAstraZenecajoint‑venture company
2026-08-05
CSPC PHARMA(01093.HK): NDA for Neoadjuvant Therapy of Anitumab Combined with HB1801 in HER2‑positive Breast Cancer Accepted and Granted Priority Review
Tags：
CSPC PHARMA01093.HKALPHAMAB-BNew Drug Application
2026-08-04
CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-03
CSPC Pharmaceutical (01093.HK): SYH2062 Hypertension Phase II Trial Initiated at First China Site; CRB-701 FDA Cleared for Pivotal OPSCC Trial
Tags：
CSPC PHARMA01093.HK
2026-07-29
CSPC Pharmaceutical (01093.HK): NDA for Sirolimus Albumin-Bound Injection Accepted by NMPA with Breakthrough Therapy and Priority Review Status
Tags：
CSPC PHARMA01093.HK
2026-07-27
CSPC Pharmaceutical (01093.HK): Paliperidone Palmitate Injection Approved for Marketing; Indicated for Schizophrenia Acute and Maintenance Treatment
Tags：
CSPC PHARMA01093.HK
2026-07-24
CSPC PHARMA (01093.HK): NDA for Envi Trastuzumab Injection Accepted by NMPA
Tags：
CSPC PHARMA01093.HKNew Drug Application
2026-07-17
CSPC Pharmaceutical Group (01093.HK): Phase II Clinical Trial of Albumin-bound Sirolimus for Injection Officially Launched
Tags：
CSPC Pharmaceutical Group01093.HK
2026-07-16
CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
Tags：
CSPC Pharmaceutical Group01093.HK
2026-07-14
CSPC PHARMA(01093.HK): Phase II Clinical Trial of SYH2070 Injection for Mixed Hyperlipidaemia Initiated at First Clinical Site in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-07-07
CSPC PHARMA(01093.HK): Enters Collaboration, Option and Licence Agreement with AstraZeneca for siRNA Drug Development with USD30 Million Upfront Payment
Tags：
CSPC PHARMA01093.HKAstraZeneca
2026-07-02
CSPC Pharmaceutical Group (01093.HK): Phase III Clinical Trial of SYS6010 Combined with Enlimomab as Adjuvant Therapy for NSCLC Officially Launched
Tags：
CSPC Pharmaceutical Group01093.HK
2026-07-01
CSPC Pharmaceutical Group (01093.HK): Second Marketing Application for Idaglutide Alpha Injection Accepted by NMPA
Tags：
CSPC Pharmaceutical Group01093.HK
2026-06-18
Previous1 23